Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 30,000 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, March 16th, Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $91.98, for a total transaction of $3,769,800.30.

Mirum Pharmaceuticals Trading Down 4.3%

Shares of MIRM stock opened at $92.17 on Wednesday. Mirum Pharmaceuticals, Inc. has a 12-month low of $43.50 and a 12-month high of $114.99. The company has a market capitalization of $5.62 billion, a P/E ratio of -6.77 and a beta of 0.50. The firm has a 50-day moving average price of $97.01 and a 200 day moving average price of $89.76. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. During the same period in the prior year, the business earned ($0.30) earnings per share. The company’s revenue for the quarter was up 43.3% on a year-over-year basis. Research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MIRM. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $165.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Royal Bank Of Canada boosted their target price on shares of Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Citigroup began coverage on shares of Mirum Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $145.00 target price for the company. Finally, Weiss Ratings downgraded shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $137.64.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Faithward Advisors LLC raised its stake in shares of Mirum Pharmaceuticals by 0.5% during the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock worth $2,537,000 after buying an additional 126 shares during the last quarter. MCF Advisors LLC raised its stake in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after buying an additional 200 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of Mirum Pharmaceuticals by 34.0% during the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after buying an additional 243 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in shares of Mirum Pharmaceuticals by 2.6% during the third quarter. Arizona State Retirement System now owns 10,984 shares of the company’s stock worth $805,000 after buying an additional 275 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.